Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Sintilimab and Bevacizumab Biosimilar in Unresectable HCC
NCT05029973Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2021
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Overall Response Rate at 2 years. Status: unknown.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05029973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029973.